Adjunctive Treatment With Doxycycline to Enhance the Durability of Endovascular Aortic Aneurysm Repair

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The durability of endovascular aneurysm repair (EVAR) has been limited by development of endoleaks which may be secondary to progressive aortic degeneration by matrix metalloproteases (MMP). Doxycycline is a known inhibitor of the MMP family of enzymes in aneurysms. The investigators propose a randomized, controlled trial of adjuvant doxycycline therapy with EVAR to determine its effects on re-intervention, aneurysm shrinkage and serum markers of aneurysmal degeneration.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Barnes-Jewish Hospital; The Foundation for Barnes-Jewish Hospital
• Treatments: Doxycycline

Criteria

Inclusion Criteria:

• Presence of an abdominal aortic aneurysm (AAA) with a maximum diameter of > or = 4.5 cm

• Planned aneurysm exclusion with endoluminal stent graft (any brand)

Exclusion Criteria:

• Known malignancy not to include prostate cancer or any history of cancer that has not had a recurrence in the last 5 years.

• Hypersensitivity to doxycycline or any of its components

• Pregnancy

• Ruptured AAA

• Extension of covered portion of the graft above the renal arteries

• Previous endoluminal aneurysm repair